期刊文献+

酮洛芬固体脂质纳米粒的制备 被引量:1

Preparation of ketoprofen solid lipid nanoparticles
在线阅读 下载PDF
导出
摘要 目的:微乳法制备固体脂质纳米粒,以酮洛芬作为模型药物,考查其载药性能。方法:通过对空白微乳粒径和稳定性考查,确定优化处方,将其保温分散于冷水中制备固体脂质纳米粒。对影响其质量的工艺因素和处方因素进行考查和优化设计,筛选最优处方。结果:制备固体脂质纳米粒的直接影响因素包括脂质用量、药物的用量、冷水相温度和微乳保温温度等,所得固体脂质纳米粒的平均粒径(143.9±1.2)nm,多分散系数为0.443。载药固体脂质纳米粒包封率为81.47%,载药量为8.16%。结论:该法稳定可靠,可用于酮洛芬固体脂质纳米粒的制备。 Objective: To prepare solid lipid nanoparticles by microemulsion technique, using ketoprofen as model drug to SLN and to investigate the drug loading capacity of SLN. Methods : Through the blank microemulsion particle size and stability test, de- termine the optimal prescription. Selection and optimization of microemulsion, the dispersed in cold water in the preparation of SLN. The influence on the quality of process factors and prescription was studied and optimized design, optimize the formulation. Results : The results showed that stearic acid dosage, dosage of ketoprofen, cold water temperature and heat preservation of microe- mulsion were the key factors that influence the preparation process of SLN, the mean size was ( 143.9 ± 1.2) nm with polydispersi- ty index of 0. 443. The best entrapment efficiency of KP - SLN was found to be 81.47% , the drug was 8.16%. Conclusion: This method is stable and reliable and can be used for ketone ibuprofen solid lipid nanoparticle preparation.
出处 《天津药学》 2014年第6期18-22,共5页 Tianjin Pharmacy
基金 天津市卫生局科技基金资助项目(No.2012KY32)
关键词 酮洛芬 微乳法 固体脂质纳米粒 包封率 ketoprofen, microemulsion, solid lipid nanoparticles, entrapment efficacy
  • 相关文献

参考文献4

二级参考文献25

  • 1王鹏,王玉珠,沈建民.均匀设计及其在药学中的应用[J].沈阳药学院学报,1989,6(4):297-305. 被引量:74
  • 2廉云飞,李娟,平其能,严菲.吲哚美辛微乳的制备及经皮吸收研究[J].中国医药工业杂志,2005,36(3):148-152. 被引量:22
  • 3[1]Muller RH, Mehnert W, Lucks JS, et al. Solid lipid nanoparticles(SLN)-an alternative colloidal carrier system for controlled drug delivery [J]. Eur J Pharm Biopharm, 1995,41(1):62-69.
  • 4[2]De Vringer T, de Ronde HAG. Preparation and structure of a water-in-oil cream containing lipid nanoparticles [J]. J Pharm Sci, 1995,84(4):466-472.
  • 5[3]Schwarz C, Mehnert W, Lucks JS, et al. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization [J]. J Controlled Release, 1994,30(1):83-96.
  • 6[4]Yang SC, Lu LF, Cai Y, et al. Body distribution in mice of intraveneously injected camptothecin solid lipid nanoparticles and targeting effect on brain [J]. J Controlled Release, 1999,59(3):299-307.
  • 7[5]Annette M, Schwarz C, Mehnert W. Solid lipid nanoparticles(SLN) for controlled drug delivery-drug release and release mechanism [J]. Eur J Pharm Biopharm, 1998,45(2):149-155.
  • 8[6]Gasco MR. Method for producing solid lipid microspheres having a narrow size distribution [P]. US Pat: 5250236,1993-10-05.
  • 9[7]Su DS. Studies on the physical properties of fat emulsion of anticancer drug [J]. J Shenyang Coll Pharm (沈阳药科大学学报), 1999,8(1):1-3.
  • 10GOOSEN C,PLESSIS D J,MULLER D G,et al.Correlation between physicochemical characteristics,pharmacokinetic properties and transdermal absorption of NSAID's[J].Int J Pharm,1998,163:203-209.

共引文献54

同被引文献15

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部